1. Early molecular response ≤1% has strong prognostic impact for CML patients that switch to second‐line therapy with BCR‐ABL1 ≤10% and no major molecular response. (18th October 2018) Authors: Bonecker, Simone; Carvalho, Gabriela; Dobbin, Jane; Zalcberg, Ilana; Schaffel, Rony Journal: British journal of haematology Issue: Volume 185:Number 4(2019) Page Start: 770 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib. Issue 6 (June 2015) Authors: Boquimpani, Carla; Schaffel, Rony; Biasoli, Irene; Bendit, Israel; Spector, Nelson Journal: Leukemia & lymphoma Issue: Volume 56:Issue 6(2015:Jun.) Page Start: 1787 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗